荷兰圆锥角膜交联评分(DUCK)的临床评估与验证
这项前瞻性队列研究在2个学术中心纳入2012至2014年转诊的圆锥角膜患者,随访2年,评估DUCK评分(基于年龄、视力、屈光、角膜曲率和主观感受5项变化)与常规最大角膜曲率增加1.0D标准的比较。结果显示采用DUCK评分使总体治疗率降低23%(95%CI 18%-30%),疾病进展风险不增加(±0%),并更好识别可暂缓治疗的眼睛35%(95%CI 22%-49%)。
要点
- DUCK评分基于5项常规临床参数变化,每项0-2分。
- 采用DUCK评分使总体治疗率降低23%(95%CI 18%-30%)。
- DUCK评分更好识别可暂缓治疗的眼睛达35%(95%CI 22%-49%)。
核心结论
- DUCK评分可作为判断圆锥角膜交联治疗是否必要的验证工具,相比常规最大角膜曲率增加超过1.0D标准,可能更好选择受益患者。
研究设计与样本
- 前瞻性队列研究,在2个学术治疗中心纳入2012年1月1日至2014年6月30日转诊的圆锥角膜患者,随访2年,分析于2017年3月开始。
- 共504只眼(388例患者)可用于12和24个月疾病进展分析。
- 发现队列与验证队列基线特征相当:年龄均值(SD)26.8(8.3)岁 vs 26.3(9.1)岁,男性比例216/332(65%) vs 123/172(72%),最大角膜曲率均值(SD)53.5(7.1)D vs 52.7(6.3)D。
主要发现
- 遵循DUCK评分而非最大角膜曲率与总体治疗率降低23%(95%CI 18%-30%)相关,且不增加疾病进展风险(两组进展率相等,±0%)。
- DUCK评分似乎更好识别可暂缓治疗的眼睛达35%(95%CI 22%-49%)。
关键数值与推荐
- DUCK评分基于5项常规评估的临床参数变化:年龄、视力、屈光误差、角膜曲率和主观患者体验,每项评分0至2分,切点由临床经验确定。
- 常规标准为过去12个月内最大角膜曲率增加超过1.0D。
临床怎么用
- DUCK评分可用于辅助决定圆锥角膜患者是否需行交联治疗,可能避免不必要的治疗、减少治疗风险暴露并提高成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Defining keratoconus progression is fundamental in clinical decision making because crosslinking treatments are indicated when the disease is considered progressive. Currently, there is no consensus which parameters should be used to define progression. OBJECTIVE: To assess and validate a novel clinical scoring system as an easy-to-use assessment tool for crosslinking treatment in patients with keratoconus. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study at 2 academic treatment centers. Patients with keratoconus referred between January 1, 2012, and June 30, 2014, with 2-year follow-up were included. Analysis began March 2017. INTERVENTIONS: The Dutch Crosslinking for Keratoconus (DUCK) score is based on changes in 5 clinical parameters that are routinely assessed: age, visual acuity, refraction error, keratometry, and subjective patient experience. The DUCK score is derived by scoring 0 to 2 points per item, and cutoffs were determined by clinical experience. We compared the DUCK scores to the conventional 1.0-diopter increase in maximum keratometry criterion, within the last 12 months, in a longitudinal discovery and a validation cohort. Sensitivity analyses and intraitem correlations were performed. MAIN OUTCOMES AND MEASURES: Overall treatment rate reduction and the duly withheld treatment rate. RESULTS: A total of 504 eyes of 388 patients were available for analysis on disease progression in the course of 12 and 24 months. Baseline patient characteristics of the discovery cohort and the validation cohort were comparable in terms of age (mean [SD], 26.8 [8.3] years vs 26.3 [9.1]), sex (216 of 332 [65%] vs 123 of 172 [72%] men), and maximum keratometry (mean [SD], 53.5 [7.1] vs 52.7 [6.3]). Adhering to the DUCK score, rather than maximum keratometry, was associated with a reduction in overall treatment rate by 23% (95% CI, 18%-30%), without increasing the risk of disease progression (ie, the rate of progression for both groups was equal; ±0%). The DUCK score appears to better identify eyes that were duly withheld treatment by 35% (95% CI, 22%-49%). CONCLUSIONS AND RELEVANCE: These results provide validation of the DUCK score as a tool to determine whether a crosslinking treatment might be warranted. Compared with the conventional maximum keratometry criterion of more than 1.0 diopter, the DUCK score may better select patients who might benefit from crosslinking treatment. Potentially, it may prevent unnecessary treatments, reduce exposure to treatment risks, and improve the cost effectiveness of crosslinking.
引用
- Wisse RPL, Simons RWP, van der Vossen MJB, et al. Clinical Evaluation and Validation of the Dutch Crosslinking for Keratoconus Score. JAMA Ophthalmol. 2019. PMID: 30920597. doi:10.1001/jamaophthalmol.2019.0415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。